Bristol Myers Squibb Secures Patent Protection Amid Upcoming Expiry
Bristol Myers Squibb gains approval to safeguard sales as the intravenous patent nears expiry, highlighting strategic pharmaceutical planning and revenue impact.
This approval could help Bristol Myers Squibb protect sales as the patent for the intravenous version will expire later this decade.